{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016262","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.180502+00:00","generated_at":"2026-05-21T16:12:16.879559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monopar Q1 net loss $2.6M, cash $54.6M; ALXN1840 NDA planned early 2026","bullets":["Cash $54.6M as of March 31, 2025; expected runway through Dec 2026 for NDA and trials.","Net loss $2.6M ($0.38/sh) vs $1.6M ($0.51/sh) YoY; R&D expense rose 70% to $1.643M.","ALXN1840 data presented at EASL; NDA submission to FDA planned early 2026.","MNPR-101-Zr and MNPR-101-Lu Phase 1 trials active in Australia; preclinical Ac-225 program advancing.","G&A expense doubled to $1.578M, driven by stock option grants and higher personnel costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016262","json":"https://secwatch.observer/filing/0001437749-25-016262.json","markdown":"https://secwatch.observer/filing/0001437749-25-016262.md","text":"https://secwatch.observer/filing/0001437749-25-016262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/0001437749-25-016262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/mnpr20250508_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:12:16.879559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}